Full Press Release Details
Ultragenyx and Kyowa Kirin Announce Intent to Submit Supplemental Biologics License Application to U.S. FDA for Crysvita (burosumab) in Tumor-Induced Osteomalacia (TIO).
RARE
Ultragenyx and Kyowa Kirin Announce Intent to Submit Supplemental Biologics License Application to U.S. FDA for Crysvita (burosumab) in Tumor-Induced Osteomalacia (TIO)
Key Takeaway: Ultragenyx and Kyowa Kirin Announce Intent to Submit Supplemental Biologics License Application to U.S. FDA for Crysvita (burosumab) in Tumor-Induced Osteomalacia (TIO)